What is the role of genetic therapies in the treatment of sinus node dysfunction (SND)?

Updated: Nov 30, 2018
  • Author: Bharat K Kantharia, MD, FRCP, FAHA, FACC, FESC, FHRS; Chief Editor: Mikhael F El-Chami, MD  more...
  • Print

Certain genetic mutations have been linked to sinus node and conduction system disease. SCN5A, HCN4, RYR2, CASQ2, and ankyrin-B (ANKB) mutations are associated with sinus node dysfunction, whereas mutations of SN5A, SCN1B, KCNJ2, TBX5, and NKX2-5 are associated with conduction system disease. Neuromuscular genetic disorders including emerin (EMD), lamin A/C (LMNA), and myotonic dystrophy type 1 (DM1) are also associated with AV conduction disease.[7] Gene- and stem cell-based therapies are currently being investigated as therapeutic options for patients with genetic or degenerative abnormalities of the cardiac electrical conduction system.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!